Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology

Genetics and Subtypes: Finding Your Child's Exact Answer

At a Glance

Leber Congenital Amaurosis (LCA) is a group of eye conditions caused by mutations in over 25 different genes. Identifying a child's exact gene through broad genetic testing is critical to predicting their vision prognosis, monitoring systemic health risks, and qualifying for targeted gene therapies like Luxturna.

It is important to understand that Leber Congenital Amaurosis (LCA) is not a single disease. Instead, it is an umbrella term for a group of genetic conditions that all lead to severe vision loss in infancy but are caused by different “broken” instructions in a child’s DNA [1][2]. Currently, mutations in over 25 different genes are known to cause LCA [1].

Why the Specific Gene Matters

Identifying your child’s exact gene is the most critical step after diagnosis. It is the “key” that unlocks three vital pieces of information:

  • The Prognosis: Some genes, like GUCY2D, are associated with very poor vision but relatively stable retinal structures for many years [3][4]. Others, like NMNAT1, can lead to rapid thinning of the retina in early childhood [5].
  • Treatment Options: The first FDA-approved gene therapy for the eye (Luxturna) only works for children with mutations in the RPE65 gene [6]. Other therapies for genes like CEP290 or AIPL1 are currently in clinical trials [7][8].
  • Systemic Health: Because some LCA genes (called ciliary genes) are also used by the kidneys, liver, or brain, knowing the gene allows doctors to monitor your child for non-eye-related health issues [9][10].
Gene Common Presentation Notable Facts
GUCY2D Severe vision loss from birth Retinal structure often looks surprisingly healthy on scans [3].
RPE65 Night blindness; slow, progressive loss Eligible for Luxturna gene therapy [6][11].
CEP290 High variability in vision loss May be associated with kidney or neurological risks [12][9].
NMNAT1 Early, rapid retinal thinning Often shows characteristic “atrophy” (wasting) in the central retina [5].
RDH12 Characteristic “watercolor” retinal patterns Typically leads to progressive vision loss in the first decade [13][14].

Decoding the Genetic Report

Genetic reports use specific terms to describe your child’s DNA. Here is what those terms mean:

  • Pathogenic: This is a “known-bad” mutation that is definitely causing the disease [15].
  • Variant of Uncertain Significance (VUS): This is a change in the DNA that doctors haven’t seen enough times to be sure if it causes disease or if it is just a normal, harmless variation [15].
  • Homozygous: The child inherited the exact same mutation from both parents.
  • Compound Heterozygous: The child inherited two different mutations in the same gene (one from each parent).
  • Autosomal Recessive: This is how most LCA is inherited. Both parents are typically “carriers” with no vision problems, but they each passed one mutated copy of the gene to their child [16]. This means there is a 25% (1 in 4) chance of this happening in future pregnancies. Consulting a genetic counselor for family planning is highly recommended.

How to Advocate for Testing

Current medical guidelines recommend comprehensive genetic testing for every patient with an inherited retinal disease [17][18].

If your doctor suggests a “targeted panel” that only looks at a few common genes, you should ask for a broad panel (which tests all known retinal genes) or Whole Exome Sequencing (WES) [19][20]. Note that broad panels or WES can take several weeks to months to return results, so setting expectations for this waiting period is important. Limited tests can miss rare or newly discovered mutations, whereas broad testing provides a much higher chance of finding the answer your child needs for future treatments [19][21].

Common questions in this guide

Why is it important to know my child's specific LCA gene?
Knowing the exact genetic mutation helps determine your child's vision prognosis and whether they qualify for specific treatments, like FDA-approved gene therapies or clinical trials. It also indicates if other organs, such as the kidneys or brain, need to be monitored.
What does a 'Variant of Uncertain Significance' (VUS) mean on my child's genetic report?
A VUS means the laboratory found a change in your child's DNA, but there is not enough medical evidence yet to confirm if it causes the disease or if it is just a normal, harmless genetic variation.
What type of genetic test is best for diagnosing Leber Congenital Amaurosis?
Medical guidelines recommend a comprehensive broad panel for inherited retinal diseases or Whole Exome Sequencing (WES). These comprehensive tests have a much higher chance of finding the specific mutation than targeted panels that only look at a few common genes.
Can Leber Congenital Amaurosis affect other parts of my child's body?
Yes. Some genetic mutations that cause LCA involve ciliary genes, which are also used by the kidneys, liver, or brain. If your child has a mutation in a gene like CEP290, doctors will recommend monitoring for non-eye-related health issues.
How is Leber Congenital Amaurosis inherited?
Most cases of LCA are inherited in an autosomal recessive pattern. This means both parents are typically healthy carriers of a mutated gene and each passed one copy to their child, resulting in a 25 percent chance of this happening in each future pregnancy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my child's report show two pathogenic mutations, or are any of the findings 'Variants of Uncertain Significance' (VUS)?
  2. 2.Is the mutation my child has eligible for any currently approved gene therapies or active clinical trials?
  3. 3.Based on my child's specific gene (like CEP290 or IQCB1), do we need to schedule baseline screenings for their kidneys or other organs?
  4. 4.Was the testing performed using a broad 'inherited retinal disease' (IRD) panel or whole exome sequencing, or was it a limited panel?
  5. 5.Can you refer us to a genetic counselor to explain the inheritance pattern and the risks for our future children or other family members?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Clinical and genetic studies for a cohort of patients with Leber congenital amaurosis.

    Zhou Y, Huang L, Xie Y, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2024; (262(9)):3029-3038 doi:10.1007/s00417-024-06450-9.

    PMID: 38662103
  2. 2

    Genetic and Clinical Profile of Retinopathies Due to Disease-Causing Variants in Leber Congenital Amaurosis (LCA)-Associated Genes in a Large German Cohort.

    Zobor D, Brühwiler B, Zrenner E, et al.

    International journal of molecular sciences 2023; (24(10)) doi:10.3390/ijms24108915.

    PMID: 37240262
  3. 3

    GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies.

    Bouzia Z, Georgiou M, Hull S, et al.

    American journal of ophthalmology 2020; (210()):59-70 doi:10.1016/j.ajo.2019.10.019.

    PMID: 31704230
  4. 4

    The Natural History of Leber Congenital Amaurosis and Cone-Rod Dystrophy Associated with Variants in the GUCY2D Gene.

    Hahn LC, Georgiou M, Almushattat H, et al.

    Ophthalmology. Retina 2022; (6(8)):711-722 doi:10.1016/j.oret.2022.03.008.

    PMID: 35314386
  5. 5

    Clinical Characterization, Natural History, and Detailed Phenotyping of NMNAT1-Associated Leber Congenital Amaurosis.

    Lee YJ, Jeong HC, Kim JH, Jo DH

    American journal of ophthalmology 2025; (271()):396-406 doi:10.1016/j.ajo.2024.12.016.

    PMID: 39710161
  6. 6

    RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies.

    Camp DA, Falabella P, Ciulla TA

    International ophthalmology clinics 2021; (61(4)):125-132 doi:10.1097/IIO.0000000000000381.

    PMID: 34584049
  7. 7

    [Polymorphism and modern diagnostic approaches for Leber congenital amaurosis].

    Khatsenko IE, Brodnitskaya EI, Kuznetsova SV

    Vestnik oftalmologii 2024; (140(5)):56-62 doi:10.17116/oftalma202414005156.

    PMID: 39569776
  8. 8

    Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.

    Michaelides M, Laich Y, Wong SC, et al.

    Lancet (London, England) 2025; (405(10479)):648-657 doi:10.1016/S0140-6736(24)02812-5.

    PMID: 39986747
  9. 9

    In vitro modeling and rescue of ciliopathy associated with IQCB1/NPHP5 mutations using patient-derived cells.

    Kruczek K, Qu Z, Welby E, et al.

    Stem cell reports 2022; (17(10)):2172-2186 doi:10.1016/j.stemcr.2022.08.006.

    PMID: 36084637
  10. 10

    Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome.

    Wu S, Yuan Z, Sun Z, et al.

    American journal of medical genetics. Part A 2022; (188(3)):948-952 doi:10.1002/ajmg.a.62582.

    PMID: 34821467
  11. 11

    RPE65 mutations in Leber congenital amaurosis, early-onset severe retinal dystrophy, and retinitis pigmentosa from a tertiary eye care center in India.

    Parameswarappa DC, Bagga DK, Upadhyaya A, et al.

    Ophthalmic genetics 2024; (45(3)):303-312 doi:10.1080/13816810.2024.2309559.

    PMID: 38323530
  12. 12

    Expanding the Clinical Spectrum of CEP290 Variants: A Case Report on Non-Syndromic Retinal Dystrophy with a Mild Phenotype.

    Esteve-Garcia A, Sau C, Padró-Miquel A, et al.

    Genes 2024; (15(12)) doi:10.3390/genes15121584.

    PMID: 39766851
  13. 13

    RDH12 retinopathy: clinical features, biology, genetics and future directions.

    Daich Varela M, Michaelides M

    Ophthalmic genetics 2022; (43(3)):301-306 doi:10.1080/13816810.2022.2062392.

    PMID: 35491887
  14. 14

    PHENOTYPIC VARIABILITY OF RECESSIVE RDH12-ASSOCIATED RETINAL DYSTROPHY.

    Zou X, Fu Q, Fang S, et al.

    Retina (Philadelphia, Pa.) 2019; (39(10)):2040-2052 doi:10.1097/IAE.0000000000002242.

    PMID: 30134391
  15. 15

    Pathogenicity Reclasssification of RPE65 Missense Variants Related to Leber Congenital Amaurosis and Early-Onset Retinal Dystrophy.

    Motta FL, Martin RP, Porto FBO, et al.

    Genes 2019; (11(1)) doi:10.3390/genes11010024.

    PMID: 31878136
  16. 16

    Ciliopathy: Senior-Løken Syndrome.

    Tsang SH, Aycinena ARP, Sharma T

    Advances in experimental medicine and biology 2018; (1085()):175-178 doi:10.1007/978-3-319-95046-4_34.

    PMID: 30578507
  17. 17

    Expanding the Mutation Spectrum for Inherited Retinal Diseases.

    Lynn J, Huang SJ, Trigler GK, et al.

    Genes 2024; (16(1)) doi:10.3390/genes16010032.

    PMID: 39858579
  18. 18

    Portuguese Society of Ophthalmology and Portuguese Society of Human Genetics Joint Clinical Practice Guidelines for Genetic Testing in Inherited Retinal Dystrophies.

    Marques JP, Soares CA, Carvalho AL, et al.

    Clinical genetics 2025; (107(6)):600-611 doi:10.1111/cge.14691.

    PMID: 39745089
  19. 19

    [Clinical and genetic aspects of inherited retinal dystrophies : Phenotypic and molecular characterization of 1000 IRD patients in a German tertiary referral center].

    Sassen SH, Kochs CL, Saßmannshausen M, et al.

    Die Ophthalmologie 2026; (123(3)):208-216 doi:10.1007/s00347-026-02383-2.

    PMID: 41603938
  20. 20

    Panel-Based Genetic Testing in a Consecutive Series of Individuals with Inherited Retinal Diseases in Australia: Identifying Predictors of a Diagnosis.

    Britten-Jones AC, Hickey DG, Edwards TL, Ayton LN

    Genes 2025; (16(8)) doi:10.3390/genes16080888.

    PMID: 40869936
  21. 21

    Unique Variant Spectrum in a Jordanian Cohort with Inherited Retinal Dystrophies.

    Azab B, Dardas Z, Aburizeg D, et al.

    Genes 2021; (12(4)) doi:10.3390/genes12040593.

    PMID: 33921607

This page provides educational information about Leber Congenital Amaurosis genetics. It does not replace professional medical advice. Always consult a pediatric ophthalmologist or genetic counselor to interpret your child's specific genetic report.

Get notified when new evidence is published on Leber congenital amaurosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.